Adjuvant chemotherapy in early stage uterine sarcomas: An open question

Uterine sarcomas are aggressive gynecological cancers even at early stage of disease. The most common histological types are represented by leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma. The mainstay of treatment of stage I-II disease is total hysterectomy with bilateral salpingo-oophorectomy. Adjuvant radiotherapy may decrease local recurrence rates without any significant impact on survival. Adjuvant chemotherapy is a logical approach, since distant recurrences are more frequent than local failures. The chemotherapy regimens commonly used in advanced uterine sarcomas are similar to the ones for advanced soft tissue sarcomas, with anthracyclines and ifosfamide as the most active drugs. However, carcinosarcomas respond better to cisplatin-based regimens. It is advisable to design international cooperative randomized trials with the aim of defining the role of adjuvant chemotherapy in the treatment of early stage uterine sarcomas.

Uterine sarcoma; Radiotherapy; Chemotherapy; Failure

[1] George M., Pejovic M. H., Kramar A. and Gynecologic Cooperating Group of French Oncology Centers: "Uterine sarcomas: prognostic factors and treatment modalities. Study on 209 patients". Gynecol. Oneal., 1986, 24, 58.

[2] Harlow B. L., Weiss N. S.. Lofton S.: "The epidemiology of sarcomas of the uterus". J. Natl. Cancer Inst., 1986, 76, 399.

[3] Kempson R. L.,B ari W.: "Uterine sarcomas. Classification, diagnosis, and prognosis". Hum. Pathol., 1970, 1, 331.

[4] Salazar O. M.,B onfiglioT .A .,P attenS .F .,K ellerB . E., Feldstem M., Dunne M. E., Rudolph J.: "Uterine sarcomas. Natural hystory, treatment and prognosis". Cancer, 1978, 42, 1152.

[5] Salazar O. M., Dunne M. E.: "The role of radiation therapy in the management of uterine sarcomas". Int. J. Radiat. Oncol. Biol Phys., 1980, 6, 899.

[6] Kahanpaa K. V., Wahlstrom T., Grohn P., Heinonen E., N1emmen U.. Widholm 0.: "Sarcomas of the uterus: a clinicopathologic study of 119 patients". Obstet. Gynecol., 1986, 67, 417.

[7] Norrs H.J., Taylor H.B.: "Mesenchyrnal tumors of the uterus". I. A clinical and pathological study of 53 endometrial stromal tumors". Cancer, 1966, 19, 755.

[8] Piver M. S., Rutledge F. N., Copeland L., Webster K.. Blumenson L., Suh O.: "Uterine endolyrnphatic stromal rnyosis: a collaborative study". Obstet. Gynecol., 1984, 64, 173.

[9] DeF usco P.A., Gaffey T.A .,M alkasian D. Jr.,L ong H.J., Cha S S.: "Endornetrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980''. Gynecol. Oncol., 1989, 35, 8.

[10] Wheelock J.B., Krebs H.B.,S chneider Y., Goplerud D. R: "Uterine sarcoma: analysis of prognostic variables in 71 cases". Am. J. Obstet. Gynecol., 1985, 151, 1016.

[11] CovensA . L.,N isker J. A., Chapman W.B .,A llen H. H.: "Utenne sarcoma: an analysis of 74 cases". Am. J. Obstet. Gynecol., 1987, 156, 370.

[12] Echt G.,J epson J.,S teel J.,L angholz B.. Luxton G.,H ernandez W. et al.:'Treatment of uterine sarcomas"．Cancer,1990, 66, 35.

[13] Malmstrom H.,S chmidt H.. Persson P. G., Carstensen J., Nordenskjold B., Simonsen E.: "Flow-cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators" Gynecol. Oneal., 1992, 44. 172.

[14] WolfsonA .H., Wolfson D. J.? Sittler S. Y.,B reton L.,M arkoeA M.. Schwade J. G. et al.: "A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas". Gynecol. Oneal., 1994, 52. 56.

[15] Olah K. S., Dunn J. A., Gee H.: "Leiomyosarcomas have a poorer prognosis than mixed rnesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma". Br. J. Obstet. Gynaecol., 1992, 99, 590.

[16] Berchuck A.. RubinS . C.. Hoskins W. J.,S aigo P. E.,P ierce V. K., Lewis J. L. Jr.: "Treatment of endornetrial stromal tumors". Gynecol. Oneal., 1990, 36, 60.

[17] StyronS .L ., BurkeT . W.,L inville W. K.: "Low-grade endometrial stromal sarcoma recurring over three decades". Gynecol. Oncol., 1989, 35, 275.

[18] Gadducci A., Sartori E.,L andoni F.. Zola P.,M aggino T., Urgesi A. et al.: "Endometrial stromal sarcoma: analysis of treatment failures and survival". Gynecol. Oncol., 1996, 63, 247.

[19] lBerchuckA .,R ubinS . C.,H oskins W. J.,S aigo P.E .,P ierce V. K., Lewis J. L. Jr.: "Treatment of uterine leiomyosarcoma". Obstet. Gynecol., 1988, 71, 845.

[20] Tinkler S. D., Cowie V. J.: "Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992". Br. J. Radiol., 1993, 66, 998.

[21] Ali S., Wells M.: "Mixed Mullerian tumors of the uterine corpus. a review". Int. J. Gynecol. Cancer, 1993, 3, 1.

[22] Gadducci A., Landoni F., Sartori E., Zola P., Maggino T., Lissom A. et al.: "Uterine leiomyosarcoma: analysis of treatment failures and survival". Gynecol. Oncol., 1996, 62, 25.

[23] Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T. et al.: "Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study". Gynecol. Oneal., 1997, 70, 67.

[24] Ayhan A., Tuncer Z. S., Tanir M., Yuce K., Ayhan A.: "Utenne sarcoma: T he Hacettepe hospital experience of 88 consecutive patients". Eur. J. Gynaecol. Oneal., 1997,18, 146.

[25] Van Dinh T., Woodruff J. D.: "Leiomyosarcoma of the uterus". Am. J. Ohstet. Gynecol., 1982, 144, 817.

[26] Gard G. B., Mulvany N. J., Quinn M. A.: "Management of uterine leiomyosarcoma in Australia. Aust NZ". J. Obstet. Gynaecol., 1999, 39, 93.

[27] Gloor E., Schnyder P.. Cikes M., Hofstetter J., Cordey R., Burmer F., Knobel P.: "Endolymphatic stromal myosis. Surgical and hormonal treatment of extensive abdominal recurrence 20 years after hysterectomy". Cancer, 1982, 50, 1888.

[28] Lantta M.,K ahanpaa K.,K arkkainen J.,L ehtovirta P.,W ahlstrom T., Widholm 0.: "Estradiol and progesterone receptors in two cases of endometriaJ stromal sarcoma". Gynecol. Oncol., 1984, 18, 233.

[29] Tsukamoto N., Kamura T., Matsukuma K., Imachi M., Uchino H., Saito T., Ono M.: "Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins". Gynecol. Oncol., 1985, 20, 120.

[30] Katz L., Merino M. J., Sakamoto H., Schwartz P. E.: "Endometrial stromal sarcoma: a clinicopathologic study of II cases with determination of estrogen and progestin receptor levels in three tumors". Gynecol. Oncol., 1987, 26, 87.

[31] Scribner D. R. Jr., Walker J. L.: "Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace" Gynecol. Oncol., 1998, 71, 458.

[32] Major F. J., Blessing J. A., Silverberg S. G., Morrow C. P., Creasman W. T., Currie J. L. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71 (4 Suppl.), 1702.

[33] Goff B. A., Rice L. W., Fleischhacker D., Muntz H. G., Falkenberry S. S., Nikrui N., Fuller A. F. Jr.: "Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence". Gynecol. Oneal., 1993, 50, 105.

[34] Arrastia C. D., Fruchter R. G., Clark M., Maiman M., Remy J.C., Macasaet M. et al.: "Uterine carcinosarcomas: incidence and trends in management and survival". Gynecol. Oncol., 1997, 65, 158.

[35] Nielsen S. N., Podratz K. C., Scheithauer B. W., O'Brien P. C: "Clinicopathologic analysis of uterine malignant mixed mullerian tumors". Gynecol. Oneal., 1989, 34, 372.

[36] Hoffman W.. Schmandt S., Kortmann R. D., Schiebe M., Dietl J., Bamberg M.: "Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases". Gynecol. Obstet. Invest., 1996, 42, 49.

[37] Chi D. S., Mychalczak B., Saigo P. E., Rescigno J., Brown C. L: "The role of whole-pelvic irradiation in the treatment of earlystage uterine carcinosarcoma". Gynecol. Oncol., 1997, 65, 493.

[38] Knocke T. H., Kucera H., Dorfler D., Pokrajac B., Potter R: "Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri". Cancer, 1998, 83, 1972.

[39] Gerszten K., Faul C., Kounelis S., Huang Q., Kelley J., Jones M W.:'The impact of adjuvant radiotherapy on carcinosarcoma of the uterus". Gynecol. Oncol., 1998,68, 8.

[40] Ferrer F., Sabater S., Farrus B., Guedea F., Rovirosa A., Anglada L. et al.: "Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita". Int. J. Radiat. Oncol. Biol. Phys., 1999, 44, 47.

[41] Yamada S. D., Burger R. A., Brewster W. R., Anton D., Kohler M. F., Monk B. J.: "Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus". Cancer, 2000, 88, 2782.

[42] Belgrad R., Elbadawi N., Rubin P.: "Uterine sarcoma". Radiology, 1975, 114, 181.

[43] Gilbert H. A., Kagan A. R., Lagasse L., Jacobs M. R., Tawa K: "The value of radiation therapy in uterine sarcoma". Obstet. Gynecol., 1975, 45, 84.

[44] Rose P. G., Boutselis J. G., Sachs L.: "Adjuvant therapy for stage I uterine sarcoma". Am. J. Obstet. Gynecol., 1987, 156, 660.

[45J Manchu! L.,P intillie M.,L efebre P.,F yles A.,K irkbride P.,L evin W., Rawlings G.: "Uterine sarcomas: prognostic factors and the role of radiation therapy". Int. J. Radiat. Oncol. Biol. Phys., 1994, 30, 284.

[46] Larson B., Silfversward C., Nilsson B., Pettersson F: "Mixed mullerian tumours of the uterus. Prognostic factors: a clinical and histopathologic study of 147 cases". Radiother. Oncol., 1990, 17, 123.

[47] EORTC-55874: "Phase Ill comparison of adjuvant radiotherapy vs observation only in patients with totally resected stage I/II highgrade uterine sarcoma". Current Clinical Trials Oncology. National Cancer Institute. PDQ, 2000, 7(3), P- l .

[48] O'Bryan R . M., Baker L . H., Gottlieb J. E., Rivkin S . E., Balcerzak S. P., Grumet G. N. et al.: "Dose response evaluation of adriamycin in human neopla、ia". Cancer, 1977, 39, 1940.

[49] Patel S. R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R. S.: "High-dose ifosfamide in bone and soft tissue sarcomas: results of phase 11 and pilot studies. Dose-response and schedule dependence". J. Clin. Oncol., 1997, 15, 2378.

[50] Benjamin R. S.,L egha S. S.,P atel S. R.,N icaise C.: "Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M. D. Anderson experience". Cancer Chemothe1: Pharmacol., 1993, 31 (Suppl. 2), S 174.

[51] Patel S. R.: "Dose-intensive chemotherapy for soft tissue sarcomas". In: "American Society of Clinical Oncology - 2000 Educatioual Book" (Perry Mc Ed.), Thirty-sixth Annual Meeting May 19-23, 2000 New Orleans, LA, 453.

[52] Patel S. R., Benjamin R. S.: "Ifosfamide in sarcomas: is it a schedule-dependent drug?". Cancer Invest., 1996, 14, 290.

[53] Bramwell V., Quirt 1., Warr D., Verma S., Young V., Knowling M., Eisenhauer E.: "Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma Canadian Sarcoma Group-National Cancer Institute of Canada Clinical Trials Group". J. Natl. Cancer inst., 1989, 81, 1496.

[54] Elias A., Ryan L., Sulkes A., Collins J., Aisner J., Antman K. H: "Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy". J. Clin. Oncol., 1989, 7, 1208.

[55] Vadhan-Raj S., Patel S., Burgess M., Papadopolous N., Plager C., Johnston T. et al.: "Phase II trial of adriamycin (A), ifosfamide (I), mesna (M) uroprotection, dacarbazine (D) (MAID) with PIX32 I (GM-CSF/IL-3 fusion protein) or G-CSF in patients (pts) with soft tissue sarcoma (STS)". Proc. Am. Soc. Clin. Oncol., 1996, 15, 525 (abstract 1696)

[56] Antman K., Crowley J., Balcerzak S. P., Rivkin S. E., Weiss G. R., Elias A. et al.: "An intergroup phase Ill randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas". J. Clin. Oncol., 1993, 11, 1276.

[57] Edmonson J. H., Ryan L. M., Blum R. H., Brooks J. S., Shiraki M., Frytak S., Parkinson D. R.: "Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas". J. Clin. Oncol., 1993, 11, 1269.

[58] Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R. et al.: "Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group". J. Clin. Oncol., 1995, 13, 1537.

[59] Frustaci S., Buonadonna A., Romanini A., Comandone A., Dalla Palma M., Gamucci T. et al.: "Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian Group on Rare Tumors". Tumori, 1999, 85, 229.

[60] Papai Z., Bodoky G., Szanto J., Poller I., Rahoty P., Eckhardt S et al.: "The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft t沁ue 、arcoma" Cancer, 2000, 89, 177.

[61] Casper E. S., Waltzman R. J., Schwartz G. K., Sugarman A., Pfister D., Ilson D. et al.: "Phase II trial of paclitaxel in patients with soft-tissue sarcoma". Cancer Invest., 1998, 16, 442.

[62] Fata F., O'Reilly E., Ilson D., Pfister D., Leffel D., Kelsen D. P. et al.: "Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face". Cancer, 1999, 86, 2034.

[63] Sandler A., Fox S., Meyers T., Rougraff B.: "Paclitaxel (taxol) plus doxorubicin plus filgrastim in advanced sarcoma: a phase II study". Am. J. Clin. Oneal., 1998, 21, 241.

[64] Santoro A.,R omanini A.,R osso A.,F rustaci S.,C omandone A., Api-ce G. et al. for the Italian group on Rare Tumors: "Lack of activity of docetaxel in soft tissue sarcomas: results of a phase II study of the Ilalian Group on Rare Tumors". Sarcoma, 1999, 3, 177.

[65] Verweij J., Lee S. M., Ruka W., Buesa J., Coleman R., van Hoessel R. et al.: "Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group". J. Clin. Oneal., 2000, 18, 2081.

[66] Antman K. H.:''Adjuvant therapy of sarcomas of soft tissue". Semin. Oneal., 1997, 24, 556.

[67] Benjamin R. S.: "Soft tissue sarcomas: biologic diversity,s taging, and need for multidisciplinary therapy". In: "American Society of Clinical Oncology - 2000 Educational Book" (Perry M. C. Ed.), Thirtysixth Annual Meeting May 19-23, 2000 New Orleans, LA, 447.

[68] "Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults". Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst. Rev. CD001419, 2000.

[69] Benjamin R. S.: "Evidence for using adjuvant chemotherapy as a standard treatment of soft tissue sarcoma". Semin. Radial. Oneal., 1999, 9, 349.

[70] Frustaci S., Gherlinzoni F., De Paoli A., Buonadonna A., Zmerly H., Fissi S. et al.: "Maintenance of efficacy of adjuvant chemotherapy (CT) in soft tissue sarcoma (STS) of the extremities up-date of a randomized trial". Proc. Am. Soc. Clin. Oneal., 1999, 18,546 (abstract 2108).

[71] Omura G. A.,M ajor F.J .,B lessingJ . A.,S edlacek T. V., ThigpenJ T., Creasman W. T., Zaino R. J.: "A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas". Cancer, 1983, 52, 626.

[72] Sutton G. P., Blessing J. A., Barret R. J., McGehee R.: "Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study". Am. J. Obstet. Gynecol., 1992, 166, 556.

[73] Sutton G., Blessing J. A., Park R., DiSaia P. J.. Rosenshein N.: "Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group". Obstet. Gynecol., 1996, 87, 747.

[74] Sutton G. P.. Blessing J. A., Rosenshein N., Photopulos G., DiSaia P. J.: "Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncologic Group study). Am J. Obstet. Gynecol., 1989, 161, 309.

[75] Sutton G., Blessing J. A., Malfetano J. H.: "lfosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study". Gynecol. Oncol., 1996, 62, 226.

[76] Leyvraz S., Bacchi M., Cerny T., Lissoni A., Sessa C., Bressoud A., Hermann R.: "Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research". Ann. Oneal., 1998, 9, 877.

[77] Thigpen J. T., Blessing J. A., Orr J. W. Jr., DiSaia P. J.: "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study". Cancer Treat. Rep., 1986, 70, 271.

[78] Thigpen J. T., Blessing J. A., Wilbanks G.D.: "Cisplatin as secondline chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group". Am. J. Clin. Oneal., 1986, 9, 18.

[79] ThigpenJ . T.,B lessingJ . A.,B eechamJ .,H omesley H.,Y ordan E: "Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study". J. Clin. Oneal., 1991, 9, 1962.

[80] Grosh W. W.,J ones H. W. 3d. Burnett L. S.. Greco F. A.: "Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy". Gynecol. Oncol., 1986, 25, 334.

[81] Kohorn E I, Schwartz P E.，Chambers J T.，Peschel R E, Kapps D. S., Merino M.: "Adjuvant therapy in mixed mullerian tumors of the uterus". Gynecol. Oneal., 1986, 23, 212.

[82] Jansen R. L., van der Burg M. E., Verweij J., Stoter G.: "Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract". Eur. J. Cancer Clin. Oneal., 1987, 23, 1131.

[83] Peters W. A. Ill, Rivkin S. E., Smith M. R., Tesh D. E.: "Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors··. Gynecol. Oneal., 1989, 34, 323.

[84] Plaxe S. C., Dottino P. R., Goodman H. M., Deligdisch L., ldelson M., Cohen C. J.: "Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy". Gynecol. Oneal., 1990, 37, 244.

[85] Baker T. R., Piver M. S., Caglar H., Piedmonte M.: "Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary". Am. J. Clin. Oneal., 1991, 14, 246.

[86] GOG-150: "Phase lII randomized study of whole abdominal radiotherapy versus chemotherapy with ifosfamide and cisplatin in patients with optimally debulked stage I, II, III, or IV carcinosarcoma of the uterus". Current Clinical Trials Oncology. National Cancer Institute". PDQ, 2000, 7(3), P-42.

[87] Sutton G., Blessing J. A., Ball H.: "Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study". Gynecol. Oneal., 1999, 74, 346.

[88] Szlosarek P. W., Lofts F. J., Pettengell R., Carter P., Young M., Harmer C.: "Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel". Anticancer Drugs, 2000, 11, 275.

[89] GOG-161: "Phase III randomized study of ifosfamide with or without paclitaxel in patients with advanced, refractory, or recurrent carcinosarcoma of the uterus". Current Clinical Trials Oncology. National Cancer Institute. PDQ, 2000, 7(3), P-324.

[90] Buchsbaum H.J., Lifshitz S., Blythe J. G.: "Prophylactic chemotherapy in stages I and II uterine sarcoma" Gynecol. Oneal., 1979, 8, 346.

[91] Marchese M. J., Liskow A. S., Crum C. P.. McCaffrey R. M., Frick H. C. 2"': "Uterine sarcomas: a clinicopathologic study, 1965-1981 ". Gynecol. Oneal., 1984, 18, 299.

[92] Van Nagell J. R. jr., Hanson M. B.. Donaldson E. S., Gallion H H.: "Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study". Cancer, 1986, 57, 1451.

[93] Wong C., Lele S. B., Natarajan N.: "Effect of adjuvant chemotherapy on long-term survival of stage I uterine sarcoma". Proc. Am. Soc. Clin. Oneal., 1999 (abstract 1492), 18, 386.

[94] Barter J. F., Smith E. B., Szpak C. A., Hinshaw W., Clarke-Pearson D. L., Creasman W. T.: "Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases". Gynecol. Oneal., 1985, 21, 220.

[95] Hannigan E. V., Freedman R. S., Rutledge F. N.: "Adjuvant chemotherapy in early uterine sarcoma". Gynecol. Oneal.,1983,15, 56.

[96] Omura G. A., Blessing J. A., Major F., Lifshitz S., Ehrlich C. E., Mangan C. et al.: "A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study". J. Clin. Oncol., 1985, 3, 1240.

[97] Hempling R. E., Piver M. S.. Baker T. R.: "Impact on progression- free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial". Am J. Clin. On col., 1995, 18, 282.

[98] Resnik E., Chambers S. K., Carcangiu M. L., Kohorn E. I., Schwartz P. E., Chambers J. T.: "A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus". Gynecol. Oncol., 1995, 56, 370.

[99] Sutton G. P.,B lessingJ . A., Carson L. F.,L entz S. S., Whitney C W., Gallion H. H.: "Adjuvant ifosfamide, mesna, and cisplatin in patients with completely resected stage I or II carcinosarcoma of the uterus: a study of the Gynecologic Oncology Group". Proc Am. Soc. Clin. Oncol., 1997 (abstract 1288), 16, 362.

[100] Kushner D. M., Webster K. D., Belinson J. L., Rybicki L. A., Kennedy A. W., Markman M.: "Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma". Gynecol. Oncol., 2000, 78, 221.